Cipla Limited (NSE: CIPLA) announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States. This collaboration reflects both companies’ shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.

Strategic Collaboration

As part of the agreement, Qilu will be responsible for development, regulatory registration, and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.

Market Expansion

Commenting on the partnership, Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio.” Marc Falkin, Chief Executive Officer, Cipla North America, added, “This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu who have been great partners.”

Future Prospects

Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, “We are pleased to establish this partnership with Cipla for QL2107. By combining our R&D and manufacturing strengths with Cipla’s U.S. commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to U.S. patients.”

As Cipla continues to expand its biosimilar portfolio, this partnership is poised to enhance its market presence and contribute to its long-term growth strategy.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cipla Limited

Cipla Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cipla moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 2.91 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 45% of its 52-week range with RSI at 38. In other words, neither side has a clear edge right now. Revenue grows at 7.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Cipla Limited.

Cipla Limited (NSE: CIPLA) announced today an exclusive licensing agreement with Sino Biopharmaceutical Limited (SBP Group) for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC). This collaboration aims to accelerate development and future access to this innovative treatment for patients with breast cancer across India, South Africa, and select emerging markets.

Strategic Partnership

Under the agreement, Cipla will receive exclusive rights to develop and commercialize TQB2102 in the licensed territories. Cipla will oversee local clinical development, regulatory activities, and commercialization, while CTTQ will manufacture and supply TQB2102. This partnership leverages SBP Group’s late-stage oncology asset and development capabilities with Cipla’s established regulatory, medical, market access, and commercial presence.

Clinical Potential

TQB2102 is being evaluated across HER2-expressing cancers and has shown promising clinical potential in HER2-low advanced breast cancer. The dual-epitope binding mode of TQB2102 aims to enhance receptor cross-linking and endocytosis efficiency, potentially offering differentiated advantages in treating patients with HER2-low expression.

As a result, this collaboration is expected to expedite local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cipla Limited

Cipla Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cipla posts a 1.6% three-month gain, but softens in the last few weeks. The PEG of 2.94 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 3.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 7.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Cipla Limited.

Cipla Limited (CIPLA) has delivered its highest-ever quarterly revenue of INR 7,119 Cr in Q1FY27, marking a significant milestone for the company. This impressive performance is driven by robust market growth and strategic expansion across various therapeutic areas. The company’s revenue growth is further supported by a strong performance in its branded prescription, trade generics, and consumer health segments.

Market Performance

The company’s One India segment, which includes Rx, Gx, and CHL, contributed 48% to the total revenue. North America accounted for 22%, while One Africa, Emerging Markets, and Europe each contributed 14%. The API and Others segment made up 2% of the revenue. Notably, the company’s EBITDA margin improved to 16.7% compared to 25.6% in the same period last year, reflecting efficient cost management.

Key Highlights

Cipla Limited has maintained its #2 rank in the overall chronic market with a chronic mix improved to 60.4%. The company continued its portfolio expansion with the launch of Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash. Additionally, Cipla’s in-house brand franchise, Dytor, has scaled to over INR 700 Cr+ in India Rx, showcasing strategic therapeutic focus. The company’s recent launches, including gProventil and gVentolin, demonstrate strong early momentum across priority therapies.

As Cipla Limited (CIPLA) continues to build a sustainable legacy for enduring growth, the company remains committed to delivering value to its stakeholders through strategic initiatives and market leadership.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cipla Limited

Cipla Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cipla posts a 8.4% three-month gain, but softens in the last few weeks. The PEG of 2.58 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 0.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 8.4% in three months on 7.2% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cipla Limited.